The pandemic imprinted a sense of purpose, urgency, and collaboration across the life sciences industry. With millions of lives and economic stability at stake, stakeholders across pharma, technology companies, and regulatory agencies proved that sling-shotting drug development from years to months when it matters the most is feasible. We need to take the scientific learnings of 2020 and accelerate them with robust engineering. The post-pandemic world will not accept the traditional missteps and realignments of pre-pandemic era drug development.
The Intelligent Clinical Cloud Print
Modified on: Fri, 5 Feb, 2021 at 3:59 PM
Did you find it helpful? Yes No
Send feedbackSorry we couldn't be helpful. Help us improve this article with your feedback.